Relationships of different blood pressure categories to indices of inflammation and platelet activity in sustained hypertensive patients with uncontrolled office blood pressure

Chronobiology International

Volumn 30, Issue 8, 2013, Pages 973-980

  Erdogan, Dogan ^a   Icli, Atilla ^a   Aksoy, Fatih ^a   Akcay, Salaheddin ^a   Ozaydin, Mehmet ^a   Ersoy, Ibrahim ^a   Varol, Ercan ^a   Dogan, Abdullah ^a  

^a SULEYMAN DEMIREL UNIVERSITY SCHOOL OF MEDICINE   (Turkey)

Author keywords

Ambulatory blood pressure; Atherosclerosis; Inflammation; Non dipper; Platelet function

Indexed keywords

ANTIHYPERTENSIVE AGENT; AUTACOID; BIOLOGICAL MARKER; C REACTIVE PROTEIN; GAMMA GLUTAMYLTRANSFERASE; URIC ACID;

ADULT; AGED; AMBULATORY CARE; ARTICLE; BLOOD; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; CHI SQUARE DISTRIBUTION; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; HYPERTENSION; IMMUNOLOGY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY; PREDICTIVE VALUE; THROMBOCYTE ACTIVATION; THROMBOCYTE VOLUME; WHITE COAT HYPERTENSION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; C-REACTIVE PROTEIN; CHI-SQUARE DISTRIBUTION; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; HUMANS; HYPERTENSION; INFLAMMATION MEDIATORS; MALE; MEAN PLATELET VOLUME; MIDDLE AGED; MULTIVARIATE ANALYSIS; OFFICE VISITS; PLATELET ACTIVATION; PREDICTIVE VALUE OF TESTS; URIC ACID; WHITE COAT HYPERTENSION;

EID: 84883565544     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2013.790045     Document Type: Article

References (38)

1. Ayala DE, Moyá A, Crespo JJ, et al. (2013). Circadian pattern of ambulatory blood pressure in hypertensive patients with and without type 2 diabetes. Chronobiol Int, 30, 99-115.
2. Bath PM, Butterworth RJ. (1996). Platelet size: measurement, physiology and vascular disease. Blood Coagul Fibrinolysis, 7, 157-61.
3. Björklund K, Lind L, Zethelius B, et al. (2004). Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men. J Hypertens, 22, 1691-7.
4. Bo S, Gambino R, Durazzo M, et al. (2005). Associations between gamma-glutamyl transferase, metabolic abnormalities and inflammation in healthy subjects from a population-based cohort: a possible implication for oxidative stress. World J Gastroenterol, 11, 7109-17.
5. Caliskan M, Erdogan D, Gullu H, et al. (2007). Association between serum gamma-glutamyltransferase levels and coronary microvascular function in hypertensive patients. J Hypertens, 25, 2497-503.
6. Campion EW, Glynn RJ, DeLabry LO. (1987). Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med, 82, 421-6.
7. Clement DL, De Buyzere ML, De Bacquer DA, et al. (2003). Prognostic value of ambulatory blood-pressure recordings in patients with treated hypertension. N Engl J Med, 348, 2407-15.
8. Coats AJ, Radaelli A, Clark SJ, et al. (1992). The influence of ambulatory blood pressure monitoring on the design and interpretation of trials in hypertension. J Hypertens, 10, 385-91.
9. Daskalopoulou SS, Khan NA, Quinn RR, et al. (2012). The 2012 Canadian hypertension education program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol, 28, 270-87.
10. D'Erasmo E, Aliberti G, Celi FS, et al. (1990). Platelet count, mean platelet volume and their relation to prognosis in cerebral infarction. J Intern Med, 227, 11-14.
11. Ermis N, Yagmur J, Acikgoz N, et al. (2012). Serum gammaglutamyl transferase (GGT) levels and inflammatory activity in patients with non-dipper hypertension. Clin Exp Hypertens, 34, 311-5.
12. Fagard RH, Celis H, Thijs L, et al. (2008). Daytime and nighttime blood pressure as predictors of death and cause-specific cardiovascular events in hypertension. Hypertension, 51, 55-61.
13. Fessel WJ. (1980). High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med, 68, 401-4.
14. Genest J, McPherson R, Frohlich J, et al. (2009). 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations. Can J Cardiol, 25, 567-79.
15. Hermida RC, Calvo C, Ayala DE, López JE. (2005). Decrease in urinary albumin excretion associated with the normalization of nocturnal blood pressure in hypertensive subjects. Hypertension, 46, 960-8.
16. Hermida RC, Ayala DE, Chayan L, et al. (2009). Administrationtime- dependent effects of olmesartan on the ambulatory blood pressure of essential hypertension patients. Chronobiol Int, 26, 61-79.
17. Hermida RC, Ayala DE, Fontao MJ, et al. (2010). Chronotherapy with valsartan/amlodipine fixed combination: improved blood pressure control of essential hypertension with bedtime dosing. Chronobiol Int, 27, 1287-303.
18. Hermida RC, Ayala DE, Mojón A, et al. (2011a). Chronotherapy with valsartan/hydrochlorothiazide combination in essential hypertension: improved sleep-time blood pressure control with bedtime dosing. Chronobiol Int, 28, 601-10.
19. Hermida RC, Chayán L, Ayala DE, et al. (2011b). Relationship between metabolic syndrome, circadian treatment time, and blood pressure non-dipping profile in essential hypertension. Chronobiol Int, 28, 509-19.
20. Hermida RC, Ayala DE, Crespo JJ, et al. (2013a). Influence of age and hypertension treatment-time on ambulatory blood pressure in hypertensive patients. Chronobiol Int, 30, 176-91.
21. Hermida RC, Ayala DE, Fernández JR, Mojón A. (2013b). Sleeptime blood pressure: prognostic value and relevance as a therapeutic target for cardiovascular risk reduction. Chronobiol Int, 30, 68-86.
22. Kaya MG, Yarlioglues M, Gunebakmaz O, et al. (2010). Platelet activation and inflammatory response in patients with nondipper hypertension. Atherosclerosis, 209, 278-82.
23. Kikuya M, Ohkubo T, Asayama K, et al. (2005). Ambulatory blood pressure and 10-year risk of cardiovascular and noncardiovascular mortality: the Ohasama study. Hypertension, 45, 240-5.
24. Lee DH, Jacobs Jr DR, Gross M, et al. (2003). Gamma-glutamyltransferase is a predictor of incident diabetes and hypertension: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem, 49, 1358-66.
25. Lee DH, Jacobs Jr DR, Gross M, Steffes M. (2005). Serum gammaglutamyltransferase was differently associated with microalbuminuria by status of hypertension or diabetes: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem, 51, 1185-91.
26. Mancia G, Omboni S, Parati G, et al. (2001). Twenty four hour ambulatory blood pressure in the Hypertension Optimal Treatment (HOT) study. J Hypertens, 19, 1755-63.
27. Mancia G, Parati G, Bilo G, et al. (2007). Assessment of long-term antihypertensive treatment by clinic an ambulatory blood pressure. Data from the ELSA Study. J Hypertens, 25, 1087-94.
28. Mansia G, De Backer G, Dominiczak A, et al. (2007). 2007 ESH-ESC Guidelines for the Management of Arterial Hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press, 16, 135-232.
29. Nadar SK, Blann AD, Kamath S, et al. (2004). Platelet indexes in relation to target organ damage in high-risk hypertensive patients: a substudy of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT). J Am Coll Cardiol, 44, 415-22.
30. Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol Int, 27, 1911-29.
31. Ruttmann E, Brant LJ, Concin H, et al. (2005). Gamma-glutamyltransferase as a risk factor for cardiovascular disease mortality: an epidemiological investigation in a cohort of 163,944 Austrian adults. Circulation, 112, 2130-7.
32. Sega R, Facchetti R, Bombelli M, et al. (2005). Prognostic value of ambulatory and home blood pressures compared with office blood pressure in the general population: follow-up results from the Pressioni Arteriose Monitorate e Loro Associazioni (PAMELA) study. Circulation, 111, 1777-83.
33. Staessen JA, Asmar R, De Buyzere M, et al. (2001). Task Force II: blood pressure measurement and cardiovascular outcome. Blood Press Monit, 6, 355-70.
34. Svensson P, de Faire U, Sleight P, et al. (2001). Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. Hypertension, 38, E28-32.
35. Tsioufis C, Syrseloudis D, Dimitriadis K, et al. (2008). Disturbed circadian blood pressure rhythm and C-reactive protein in essential hypertension. J Hum Hypertens, 22, 501-8.
36. Turnbull F; Blood Pressure Lowering Treatment Trialists' Collaboration. (2003). Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 362, 1527-35.
37. Verdecchia P, Schillaci G, Borgioni C, et al. (1997). Altered circadian blood pressure profile and prognosis. Blood Press Monit, 2, 347-52.
38. Ward HJ. (1998). Uric acid as an independent risk factor in the treatment of hypertension. Lancet, 352, 670-1.